WilmerHale Advises Embark Veterinary in $75M Series B Funding

WilmerHale Advises Embark Veterinary in $75M Series B Funding

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On July 26, 2021, Embark Veterinary, Inc., the top rated provider of dog DNA tests, announced that it secured $75 million in a Series B funding round led by SoftBank, with additional investors including F-Prime Capital, Slow Ventures, Freestyle Capital and Third Kind Venture Capital. Embark’s DNA-based analytics seeks to curb preventable diseases and increase the lifespan of dogs. The funding will be used to expand hiring and accelerate the development of Embark’s robust discovery engine.

The team representing Embark consisted of David A. Westenberg, Jon Jones, J.P. Mohler, and Cindy Sullivan.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel